Beam Therapeutics BEAM Derivative Liabilities - Fair Value
Derivative Liabilities - Fair Value at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's derivative liabilities - fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's derivative liabilities - fair value?
- Beam Therapeutics (BEAM) reported derivative liabilities - fair value of $5.2M in Q1 2026.
- How has Beam Therapeutics's derivative liabilities - fair value changed year-over-year?
- Beam Therapeutics's derivative liabilities - fair value decreased by 0.0% year-over-year, from $5.2M to $5.2M.
- What is the long-term trend for Beam Therapeutics's derivative liabilities - fair value?
- Over 5 years (2020 to 2025), Beam Therapeutics's derivative liabilities - fair value has grown at a -35.9% compound annual growth rate (CAGR), from $71.2M to $7.7M.
- What does derivative liabilities - fair value mean?
- This metric represents the total fair market value of all derivative contracts currently in a liability position for the institution. It reflects the potential cash outflow required if these contracts were settled at the current reporting date. Monitoring this value is essential for assessing the bank's exposure to market volatility and counterparty risk.